Full Text CA-95-006 DEVELOPMENT GRANTS FOR NEW RESEARCH PROGRAMS IN PROSTATE CANCER NIH GUIDE, Volume 24, Number 4, February 3, 1995 RFA: CA-95-006 P.T. 34 Keywords: Cancer/Carcinogenesis Urogenital System Biomedical Research, Multidiscipl Disease Prevention+ National Cancer Institute National Institute of Environmental Health Sciences Letter of Intent Receipt Date: March 3, 1995 Application Receipt Date: April 7, 1995 PURPOSE This Request for Application (RFA) is sponsored by the Cancer Centers Branch of the Division of Cancer Biology, Diagnosis and Centers (DCBDC) at the National Cancer Institute (NCI), and the Chemical Exposures and Molecular Biology Branch, Division of Extramural Research and Training (DERT), National Institute of Environmental Health Sciences (NIEHS). The co-sponsoring institutes invite grant applications for development of new research programs in Prostate Cancer. The intent of this Request for Application (RFA) is to promote through the use of the exploratory/developmental grant mechanism (R21), development of interactive, multidisciplinary basic, clinical, and prevention and control research base at the applicant institution. Because basic research in prostate cancer has lagged behind that of other solid tumors, emphasis on the plans for developing basic research studies of prostate cancer is encouraged; however, such studies should consider the opportunities for interactive basic and clinical research and its potential for translational research. The major goal of this initiative is to promote development of research focused on prostate cancer. While basic laboratory research should be the foundational component of the application, every applicant is encouraged to consider including the elements that address the special emphasis areas of environmental and occupational carcinogenesis, prevention and control research opportunities, and/or the unusually high incidence and mortality rates in underserved minority or other high risk populations. This initiative should provide applicant institutions opportunities to significantly expand the interactive, peer-reviewed, funded research base (e.g., R01s, P01s) on prostate cancer. Each institution should provide a comprehensive plan for achieving this objective, which utilizes innovative exploratory studies (i.e., pilot/feasibility studies) as a basis for establishing long-term peer-reviewed funding, and new recruitment, as a way of attracting critical scientific expertise. This initiative should help the institution build a stable, competitive research base that is interactive between the basic, clinical, and prevention and control sciences, and that will position the institution to have an impact on reducing the incidence and mortality of prostate cancer through research. HEALTHY PEOPLE 2000 The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2000," a PHS-led national activity for setting priority areas. This RFA, Development Grants for Research Programs in Prostate Cancer, is related to the priority area of cancer. Potential applicants may obtain a copy of "Healthy People 2000" (Full Report: Stock No. 017-001-00474-0 or Summary Report: Stock No. 017-001-00473-1) through the Superintendent of Documents, Government Printing Office, Washington, DC 20402-9325 (telephone 202-783-3238). ELIGIBILITY REQUIREMENTS All domestic non-profit and for-profit institutions are eligible to apply for this initiative. Foreign organizations and/or domestic applications with international components are not eligible for this initiative. Because the intent of the RFA is to encourage development of institution-wide, multidisciplinary, research programs in prostate cancer, only one application per institution may be submitted. At those institutions that are NCI-designated Cancer Centers, the prostate cancer program should become an integral component of the cancer center and, as such, should benefit from the spectrum of resources, the patient base of the center, as well as participate in the interactive infrastructure of the center. The application must confirm this arrangement by including a statement co-signed by the Principal Investigator of the proposed R21 grant and the Center Director. Institutions with P20 Feasibility Specialized Programs of Research Excellence (SPORE) grants in prostate cancer are eligible to apply. However, institutions that already have prostate cancer research programs supported by the P30 Cancer Center Support Grants (CCSG) and/or P50 SPOREs in prostate cancer research can apply only for the purpose of expanding their research base in environmental carcinogenesis and occupational carcinogenesis, and in minority, and other underserved, high risk special populations where prostate cancer incidence and mortality are disproportionately higher in their regions of influence. MECHANISM OF SUPPORT This RFA will use the National Institutes of Health (NIH) exploratory/developmental grant (R21) mechanism. Responsibility for the planning, direction, and execution of the proposed project will be solely that of the applicant. The total project period for an application submitted in response to this RFA may not exceed four years. The anticipated award date is September 1, 1995. Because the nature and scope of the proposed developing program may vary, it is anticipated that the size of an award will vary also. This RFA is a one-time solicitation. FUNDS AVAILABLE The NCI anticipates setting aside approximately $1.5 million in total costs in FY 1995 to fund the applications submitted in response to this RFA. The budget request is limited to $300,000 total costs per year, and the total award period will be for no more than four years. The NCI anticipates funding at least five applications. This funding level is dependent on the receipt of a sufficient number of applications of high scientific merit. Although this program is provided for in the financial plans of the NCI, the award of grants pursuant to this RFA is contingent upon availability of funds for this purpose. No funds are obligated by the NIEHS at this time. However, based on funds that may be available at a later date, the NIEHS may co-fund several applications with the NCI. RESEARCH OBJECTIVES Background and Scope Prostate cancer, now the most common cancer in United States males, is the second leading cause of cancer deaths in men. At present, this disease results in more than 38,000 deaths annually. African- American males have the highest prostate cancer incidence in the world, with two-fold higher mortality rates than in white males. The reasons for this racial difference are unclear, although environmental, dietary, and hormonal factors are under study. A recent analysis of mortality data comparing deaths due to prostate cancer in African-American farming populations from three southeastern states compared to 21 northeast and north central states indicated 38 percent higher incidence of prostate cancer deaths in the African-American farmers in the southeast relative to those in the other 21 states examined (JNCI, 86:1718-1719, 1994). This study supports the notion of association of prostate cancer risk and certain occupations, and the need for multidisciplinary efforts in prostate cancer research focused on environmental and occupational risk factors. The economic burden of prostate cancer in terms of direct medical expenses alone, including a quarter of a million hospitalizations, is estimated to cost upwards of $1.5 billion annually. Prostate cancer research has lagged far behind research in other major forms of cancer, and there has been a lack of new investigators entering the field. In part, this has been due to lack of suitable in vitro and in vivo model systems and lack of accessibility to human prostate tissues. Effective reduction of incidence and mortality due to prostate cancer will require a concerted effort to expand the opportunities and the scientific information base. The prostate cancer problem offers challenging opportunities in both basic and clinical scientific research. It has also attracted public attention as a major disease threat directly affecting the lives of thousands of men. It is expected that in developing a new research program in prostate cancer, innovative pilot projects and recruitment of new investigators to be supported by this initiative will emphasize a mix of interactive basic, clinical, and prevention and control research, placing special emphasis on issues of environmental and occupational carcinogenesis, and of unusually high incidence and mortality in minority and other underserved high risk populations. The special feature of this initiative is to develop a highly interactive research program in prostate cancer by providing opportunities for bringing together investigators with mutual and complementary interests to engage in prostate cancer research, new recruitment, and for pilot/feasibility studies focused on the prostate cancer problem that will lead to establishment of an interactive, multidisciplinary research base in prostate cancer at the applicant institution. SPECIAL REQUIREMENTS The purpose of this RFA is to promote development of a new, broad, interactive research base (e.g., R01s, P01s) at the applicant institutions for the conduct of multidisciplinary research in prostate cancer, placing special emphasis on issues of environmental and occupational carcinogenesis, and prevention and control research. The ultimate objective is to reduce incidence and mortality, and to increase and improve survival to the disease. An important aspect of this initiative is to examine the extent and impact that environmental and occupational exposures contribute to prostate cancer incidence and mortality among minority and other underserved populations, and to develop effective means of cancer prevention and control in these special populations. The application must demonstrate commitment and potential for establishing a new research program in prostate cancer, which when fully developed, should have a substantial, interactive, multidisciplinary peer-reviewed funded research base of basic science and clinical research, and prevention and control research investigators engaged in prostate cancer research. Likewise, the P30 CCSG and/or P50 SPORE grantees, must demonstrate the potential of expanding the research base of their existing prostate cancer program into the special emphasis areas and the resultant impact on the incidence and morbidity of the disease. The exploratory developmental grant mechanism provides funds in areas that can be used flexibly for development of new multidisciplinary research program as follows: (a) planning activities, (b) pilot projects, and (c) recruitment of new investigators. The application should provide a detailed plan by which the requested funds in these areas will be used in a balanced way over the proposed grant period to achieve the objectives. Each application must include the following elements listed below. Additional considerations are noted at the end of this section for those institutions with existing prostate cancer programs supported by the P30 CCSG and/or P50 SPORE mechanisms. 1. Institutional commitment: The institution should delineate special commitments that go beyond those associated with regular research grant applications (e.g., R01s), that demonstrate how this program will be given a high priority development, and that will improve chances for success if an award is made. These special commitments may be in the form of commitments to recruit new scientific talent, administrative resources, provision of discretionary resources to the program, assignment of contiguous research space, cost-sharing of centralized resources, or other ways to be proposed by the applicant. 2. Qualified Principal Investigator/Program Director: A leader should be selected as Principal Investigator/Program Director who can oversee and conduct planning activities, provide direction to the developing program and ensure a multidisciplinary research emphasis. Describe the scientific qualifications and administrative competence of the proposed individual for directing the planning and development effort. This individual must devote a significant proportion of his/her time to this endeavor. 3. Planning and evaluation process: The application should describe a planning and evaluation process for the developing program. For example, it could include an internal planning committee composed of senior leaders of the institution that will assist the Principal Investigator in developing the program. Where special input may be necessary, highly regarded specialists in prostate cancer research may be used as external advisors on an ad hoc basis. The application should address the process for prioritizing and distributing resources among (a) pilot/feasibility studies, (b) recruitment of new investigators, and (c) retreats and meetings. 4. Plan: The application must provide a plan for developing a program with sufficient scientific breadth and depth, that is cohesive, multidisciplinary, and takes maximum advantage of the institution's resources and research capabilities. The planned program would be expected to identify a nucleus of investigators knowledgeable of and involved in prostate cancer research, and to identify and bring together new investigators in and outside the institution who wish and can contribute to the development of basic, clinical, and prevention and control research in prostate cancer, and in the special emphasis areas, where applicable. The application should describe how this existing research base will coalesce within the plans of a new developing program. This initiative includes recruiting new investigators and supporting pilot projects/feasibility studies. The proposed plan should fully describe how this new recruitment and support of pilot studies would enhance the expertise, strengthen and/or broaden the research base of the program, and enhance the special emphasis areas, thereby creating a more productive, interactive research environment. 5. Exploratory pilot studies: The most significant portion of the budget should focus on initiating novel pilot projects or feasibility studies that will stimulate basic, clinical, and prevention and control research in prostate cancer. It is expected this would help build the peer-reviewed, funded research base in support of prostate cancer, and at the same time enhance the research capabilities of the institution in special emphasis areas. It is also expected that interactive pilot studies will have the potential to facilitate translational research. The application should include a plan and rationale for selecting the emphasis areas for pilot projects/feasibility studies. Pilot projects or feasibility studies may be collaborative among scientists. It is important that the funds requested in this category are for pilot/feasibility studies that take maximum advantage of new research opportunities. The application should include the process for selecting pilot studies for funding that represent the most innovative ideas, are likely to have the greatest impact on reducing prostate cancer incidence and mortality, and are most likely to result in expanding the funded research base of the program. A proposed list of pilot projects/feasibility studies should be presented highlighting those that would be selected for initial funding. For the projects selected for initial funding, a scientific plan in sufficient detail for peer-review should be included in the body of the application. The scientific plan must not exceed three pages, and should include short introduction, hypothesis, experimental approach, expected results, and its significance to prostate cancer. The expectation is that successful pilot studies will become fully developed projects within the program, and be submitted as research projects for competitive support (e.g., R01s, P01s). New innovative pilot studies may be initiated during the award period if approved by the institutional selection and planning process. However, the NCI staff should be informed of such additions and/or changes. Abstracts of pilot studies to be selected by the institutional selection process for funding in subsequent years of the award period should not exceed one page, and, for each pilot study, should include the hypothesis, specific aims, methods of approach, and significance to prostate cancer. These should be appended to the application. 6. Recruitment of new investigators: A strong expectation is that the proposed plan will identify the expertise of some new investigators who will be recruited to the institution and strengthen and/or broaden the research base of the program by enhancing special emphasis areas and/or creating a more productive, interactive research environment. 7. A substantial prostate cancer patient population: When fully developed, each program should be recognized as a substantive interactive program in innovative basic and clinical research, and prevention and control research, with a high degree of opportunity for moving basic research findings into the patient and population research settings. The application must demonstrate and document access to a patient population that can benefit from the opportunities provided by this initiative. Additional considerations for special emphasis applications from institutions with existing prostate cancer programs funded by the P30 CCSG and/or P50 SPORE mechanisms will be: o Principal Investigator/Program Director: It is expected that the Program Director of the existing prostate cancer program will be the Principal Investigator/Program Director of this developing program. o Description of the existing prostate cancer research program and explanation as to how it will complement and enhance new research efforts in the special emphasis areas, i.e, environmental and occupational carcinogenesis, and of unusually high incidence and mortality in minority and other underserved high risk populations. o All elements (e.g., exploratory pilot studies, recruitment, etc.) of the application should focus on strengthening the special emphasis areas described above. INCLUSION OF WOMEN AND MINORITIES IN RESEARCH INVOLVING HUMAN SUBJECTS It is the policy of the NIH that women and members of minority groups and their subpopulations must be included in all NIH supported biomedical and behavioral research projects involving human subjects, unless a clear and compelling rationale and justification is provided that inclusion is inappropriate with respect to the health of the subjects or the purpose of research. This new policy results from the NIH Revitalization Act of 1993 (Section 492B of Public Law 103-43) and supersedes and strengthens the previous policies (Concerning the Inclusion of Women in Study Populations, and Concerning the Inclusion of Minorities in Study Populations) which have been in effect since 1990. The new policy contains some new provisions that are substantially different from the 1990 policies. All investigators proposing research involving human subjects should read the "NIH Guidelines on the Inclusion of Women and Minorities as Subjects in Clinical Research", which have been published in the Federal Register of March 28, 1994 (FR 59 14508-14513) and reprinted in the NIH Guide for Grants and Contracts, Volume 23, Number 11, March 18, 1994. Investigators may obtain copies from these sources or from the program staff listed under INQUIRIES. Program staff may also provide additional relevant information concerning the policy. LETTER OF INTENT Prospective applicants are asked to submit, by March 3, 1995, a letter of intent that includes a descriptive title of the proposed application, the name, address, and telephone number of the Principal Investigator, the identities of other key personnel and participating institutions, and the number and title of the RFA in response to which the application may be submitted. Although a letter of intent is not required, is not binding, and does not enter into the review of a subsequent application, the information it contains allows the NCI staff to estimate the potential review workload and avoid conflict of interest in review. It will also allow the NCI program staff to contact potential applicants and provide them with the earliest opportunity possible to obtain clarifications of the initiative and to prepare the most competitive application possible that meets all of the requirements of the initiative. The letter of intent is to be sent to Dr. Jaswant S. Bhorjee at the address listed under INQUIRIES. APPLICATION PROCEDURES The research grant application form PHS 398 (rev. 9/91) is to be used in applying for these grants. These forms are available at most institutional offices of sponsored research; from the Office of Grants Information, Division of Research Grants, National Institutes of Health, 5333 Westbard Avenue, Room 449, Bethesda, MD 20892, telephone 301-710-0267; and from the program administrator listed under INQUIRIES. Although form PHS 398 was developed for investigator-initiated research applications, the instructions in the PHS 398 application kit must be followed where appropriate. Applications must meet all eligibility requirements as described above and must address all programmatic requirements (see SPECIAL REQUIREMENTS above) in the RFA. In preparing the written application, the applicant should also examine the review criteria provided under the REVIEW CONSIDERATIONS section. The application must contain the following elements and supporting documents noted below: 1. Plan for the development of the program should be presented in the Research Plan section of the PHS 398 application. This section should address the elements noted under SPECIAL REQUIREMENTS above, and should not exceed 40 pages. 2. Overall and Individual Budgets and Justifications: An individual budget should be submitted for individual areas of 'Principal Investigator/Program Director', 'pilot studies', 'recruitment of new investigators', and 'planning and evaluation'. The R21 Developmental Grant will support the following budgetary items: o Partial salary of the Principal Investigator/Program Director. o Funds for pilot studies in support of technical assistance and/or conduct of research. o Partial funds for recruitment of new investigators. The intent is to co-share support with the institution for costs of salary and recruitment package so that more recruitment opportunities may be created. o Planning and evaluation funds to support the travel and per diem costs of outside advisors or consultants during the initial phases of planning. Also minimal funds for special retreats and meetings for the purpose of prostate cancer program development. 3. Biographical sketches of all key personnel and outside consultants (use PHS 398 format). The publications listed as part of the biographical sketches should highlight those that are relevant to prostate cancer research. 4. Supporting Documents: o Research Grants and Contracts. Provide a list of all active funded cancer and cancer related research grants and contracts that may constitute the initial research base of the proposed program. The projects should be listed in alphabetical order by PI name, and should be presented in a table format to include PI name, funding agency (if NIH, identify sponsoring institute, i.e., CA, AG, ES), I.D. number, project title, grant award period, total direct costs, and current annual direct costs. o Letters or documents from senior officials of the institution documenting institutional support for the proposed planning and development process. Co-signed letter by the Principal Investigator and the Cancer Center Director of the institution in an NCI- designated Cancer Center supported by a P30 CCSG. The RFA label available in the application form PHS 398 (rev. 9/91) must be affixed to the bottom of the face page of the application. Failure to use this label could result in delayed processing of the application such that it may not reach the review committee in time for review. In addition, the RFA title and number must be typed on line 2a of the face page of the application form and the YES box must be marked. Submit a signed, typewritten original of the application, including the Checklist, and three signed, photocopies, in one package to: Division of Research Grants National Institutes of Health Westwood Building, Room 240 Bethesda, MD 20892** At the time of submission, two additional copies of the application must be sent to: Ms. Toby Friedberg Division of Extramural Activities National Cancer Institute Executive Plaza North, Room 636 6130 Executive Boulevard Bethesda, MD 20892-7405 (if using U.S. Postal service) Rockville, MD 20852 (if express mail or carrier service) Applications must be received by April 7, 1995. Applications received after this date will not be accepted. Also, the Division of Research Grants (DRG) will not accept any application in response to this RFA any part of which is the same as one currently being considered by any other review group or NIH awarding unit. REVIEW CONSIDERATIONS Review Procedures Upon receipt, applications will be reviewed initially for completeness by DRG and responsiveness by the NCI. Incomplete applications that have not addressed all of the required elements noted under SPECIAL REQUIREMENTS or that do not meet the eligibility requirements as noted above, will be returned to the applicant without further consideration. Evaluation for responsiveness to the program requirements stated in the RFA is an NCI program staff function; this will be done stringently and will be based primarily on the clear orientation of the application to human prostate cancer. Applications judged to be non-responsive to this RFA will be returned without review. Applications that are complete and responsive to this RFA will be evaluated for scientific and technical merit and for special requirements of the RFA by an appropriate peer-review group convened by the NCI in accordance with the review criteria stated below. The second level of review will be performed by the National Cancer Advisory Board and/or National Advisory Environmental Health Services Council. Review Criteria The major factors to be considered in the evaluation of all applications are given below. Additional factors are noted in a separate section for applications from institutions with existing P50 SPOREs in prostate cancer and/or with an established prostate cancer research program as part of a P30 Cancer Center Support Grant. 1. The Institutional Commitment o adequacy of space and other normal institutional resources to promote development of the proposed prostate cancer research program; o strength of the special commitments of the institution, which will enhance the successful development of a prostate cancer research program (e.g., commitments to positions, discretionary resources for the Principal Investigator, specialized space). 2. Overall Program Organization and Capability o the scientific qualifications and demonstrated leadership capabilities of the proposed Principal Investigator/Program Director; adequacy of the time commitment of the Principal Investigator/Program Director for the demands of a developing program; o the potential effectiveness of planning and evaluation process, including internal advisory groups and consultants; adequacy and qualifications of proposed advisory membership; adequacy and effectiveness of the decision making process, particularly with respect to planning the program research directions, enhancing interactive and collaborative efforts, and allocating funds for new recruitment and pilot studies, including the special emphasis areas, where appropriate; o adequacy of the proposed development plan, including development of a cohesive, focused research theme, consideration of special emphasis areas, where appropriate, and vision for the future of the program; adequacy of prostate cancer or related ongoing research activities (e.g., funded research projects) as a foundation upon which to build a substantial multidisciplinary research program in prostate cancer; o overall general adequacy of the proposed pilot projects/feasibility studies in terms of their innovativeness and likelihood of advancing the knowledge base in prostate cancer, improving overall research capability, stimulating interactive research between basic science and clinical research investigators, prevention and control research, and their potential for facilitating translational research; adequacy and potential of the pilot studies in building the peer-reviewed funded research base of the prostate cancer program (specific evaluation of pilot studies for merit is in the next section); o adequacy of plans and priorities for recruitment of new investigators for the specific purpose of creating a broad, interactive and interdisciplinary program, and/or for enhancing special emphasis areas; o adequacy of access to patients and to a population for conducting of potential new therapeutic, prevention and control research; at institutions where immediate access to patient populations is not available, adequacy of plans to access patient populations for clinical research and/or collaborations with clinical investigators; o the adequacy of the procedures, processes, and plans for promoting interactions. o Adequacy of plans to include minorities and their subgroups as appropriate for the scientific goals of the research. Plans for the recruitment and retention of subgroups will also be evaluated. 3. Individual Pilot Projects/Feasibility Studies o scientific merit of the proposed pilot/feasibility study; o qualifications and demonstrated competence of the investigators to conduct the proposed research; adequacy of all key laboratory and clinical personnel associated with the pilot project; o degree to which the proposed pilot project addresses an issue of substantive importance for enhancing knowledge base in human prostate cancer; o originality, novelty, and innovativeness of the proposed pilot project and its relevance to the overall goals and objectives of the RFA; o potential of the degree to which the proposed pilot project/study is likely to promote basic/clinical interactions and will be interactive with other pilot studies in the program. The above criteria apply to all competing applications, including the special emphasis applications. Additionally, the special emphasis applications will be evaluated for how well the existing prostate cancer research program complements and enhances new research efforts in the special emphasis areas, i.e., environmental and occupational carcinogenesis, and of unusually high incidence and mortality in minority and other underserved high risk populations. The reviewers will be asked to recommend a period of time for support (not to exceed four years) and budget for each year approved not to exceed the dollar limit set forth in the RFA. AWARD CRITERIA The earliest anticipated date of award is September 1, 1995. The following will be considered in making funding decisions: (a) priority score, (b) availability of funds, and (c) programmatic priorities. INQUIRIES Inquiries concerning this RFA are encouraged. The opportunity to clarify any issues or questions from potential applicants is welcome. Direct inquiries regarding programmatic issues to: Jaswant S. Bhorjee, Ph.D. Division of Cancer Biology, Diagnosis, and Centers National Cancer Institute Executive Plaza North, Room 502 6130 Executive Boulevard MSC 7386 Bethesda, MD 20892-7386 Telephone: (301) 496-8531 FAX: (301) 402-0181 Email: bhorjeej@dcbdcep.nci.nih.gov Gwen W. Collman, Ph.D. Division of Extramural Research and Training National Institute of Environmental Health Sciences P.O. Box 12233 Research Triangle Park, NC 27709 Telephone: (919) 541-4980 FAX: (919) 541-2843 Direct inquiries regarding fiscal matters to: Carolyn Mason Grants Administration Branch National Cancer Institute Executive Plaza South, Room 243 6120 Executive Boulevard MSC 7150 Bethesda, MD 20892-7150 Telephone: (301) 496-7800 ext. 259 Dorothy Williams Grants Management Specialist National Institute of Environmental Health Sciences Building 2, Mail Drop 2-01 P.O. Box 12233 Research Triangle Park, NC 27709 Telephone: (919) 541-2749 AUTHORITY AND REGULATIONS This program is described in the catalog of Federal Domestic Assistance Number 93.397. Awards are made under authorization of the Public Health Service Act, Title IV, Part A (Public Law 78-410, as amended by Public Law 99-158, 42 USC 241 and 285) and administered under PHS grants policies and Federal Regulations 42 CFR Part 52 and 45 CFR Part 74. This program is not subject to the intergovernmental review requirements of Executive Order 12372 or Health Systems Agency review. The PHS strongly encourages all grant recipients to provide a smoke- free workplace and promote the non-use of all tobacco products. This is consistent with the PHS mission to protect and advance the physical and mental health of the American people. .
Return to NIH Guide Main Index
Office of Extramural Research (OER) |
National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892 |
Department of Health and Human Services (HHS) |
||||||||
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files. |